Is CD20 the only target available for radionuclide therapy in lymphoproliferative disorders?

Eur J Haematol. 2005 May;74(5):450-1. doi: 10.1111/j.1600-0609.2005.00408.x.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antigens, CD20 / blood*
  • Humans
  • Lymphoproliferative Disorders / radiotherapy*
  • Male
  • Middle Aged
  • Octreotide / analogs & derivatives*
  • Treatment Outcome
  • Yttrium Radioisotopes

Substances

  • Antigens, CD20
  • Yttrium Radioisotopes
  • 90Y-octreotide, DOTA-Tyr(3)-
  • Octreotide